Cabotegravir, rilpivirine combo meets primary endpoint in HIV-1 phase 3 trial

Image: Cabotegravir, rilpivirine combo succeeds in ATLAS-2M phase 3 trial in HIV-1. Photo: courtesy of Darwin Laganzon/Pixabay.